Preclinical Models for Bladder Cancer Research.

Preclinical Models for Bladder Cancer Research.
复制标题

DOI:
10.1016/j.hoc.2021.02.007
复制
发表时间:
2021-06
期刊:
Hematology/oncology clinics of North America
影响因子:
--
通讯作者:
Pan CX
Pan CX
中科院分区:
其他
文献类型:
--
作者:
Zhu S;Zhu Z;Ma AH;Sonpavde GP;Cheng F;Pan CX

文献摘要

参考文献

被引文献

相似文献

在诊断时,超过70%的膀胱癌(BC)处于非肌层浸润性膀胱癌(NMIBC)阶段,其通常用经尿道切除术随后膀胱内灌注治疗。对于其余的晚期癌症,全身治疗是护理标准,在局部晚期癌症的情况下添加根治性环磷酰胺。由于治疗方式的差异,需要不同的模式来推进NMIBC和晚期BC的护理。本文对体外和体内BC模型进行了全面的综述,并比较了这些临床前系统在BC研究中的优缺点。
At diagnosis, over 70% of bladder cancers (BC) are at the non-muscle-invasive bladder cancer (NMIBC) stages which are usually treated with transurethral resection followed by intravesical instillation. For the remaining advanced cancers, systemic therapy is the standard of care with addition of radical cystectomy in case of locally advanced cancers. Because of the difference in treatment modalities, different models are needed to advance the care of NMIBC and advanced BC. This article gives a comprehensive review of both in vitro and in vivo BC models and compares the advantages and drawbacks of these preclinical systems in BC research.
DOI: 10.1038/nm.3954
发表时间: 2015-11-01
期刊: NATURE MEDICINE
影响因子: 82.9
作者:
Gao, Hui;Korn, Joshua M.;Sellers, William R.
通讯作者: Sellers, William R.
DOI: 10.1016/j.juro.2009.08.020
发表时间: 2009-12-01
期刊: JOURNAL OF UROLOGY
影响因子: 6.6
作者:
Chan, Eddie S. Y.;Patel, Amit R.;Larchian, William A.
通讯作者: Larchian, William A.
DOI: 10.1016/j.urolonc.2008.02.015
发表时间: 2009-05-01
影响因子: 2.7
作者:
Dhawan, Deepika;Ramos-Vara, Jose A.;Knapp, Deborah W.
通讯作者: Knapp, Deborah W.
DOI: 10.1093/nar/gkp995
发表时间: 2010-01-01
影响因子: 14.9
作者:
Forbes, Simon A.;Tang, Gurpreet;Futreal, P. Andrew
通讯作者: Futreal, P. Andrew
DOI: 10.1002/0471141755.ph1414s49
发表时间: 2010-06
影响因子: --
作者:
Seager, Catherine;Puzio-Kuter, Anna M;Cordon-Cardo, Carlos;McKiernan, James;Abate-Shen, Cory
通讯作者: Abate-Shen, Cory